Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Reproxalap

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 223,040Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aldeyra Announces FDA Review of Reproxalap for Dry Eye Disease
    Aldeyra Announces FDA Review of Reproxalap for Dry Eye Disease

    18 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241118246408/en

    BUSINESSWIRE
    18 Nov 2024
    Share Share
    Aldeyra Therapeutics Achieves Primary Endpoint In Dry Eye Disease Trial
    Aldeyra Therapeutics Achieves Primary Endpoint In Dry Eye Disease Trial

    08 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240808408806/en

    BUSINESSWIRE
    08 Aug 2024
    Share Share
    Aldeyra Schedules Call For Phase 3 Dry Eye Trial Results Of Reproxalap
    Aldeyra Schedules Call For Phase 3 Dry Eye Trial Results Of Reproxalap

    07 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240807851086/en

    BUSINESSWIRE
    07 Aug 2024
    Share Share
    Aldeyra Completes Enrollment In Phase 3 Reproxalap Dry Eye Disease Trial
    Aldeyra Completes Enrollment In Phase 3 Reproxalap Dry Eye Disease Trial

    13 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240613335679/en

    BUSINESSWIRE
    13 Jun 2024
    Share Share
    Aldeyra Therapeutics: Phase 3 Trial for Reproxalap in Dry Eye
    Aldeyra Therapeutics: Phase 3 Trial for Reproxalap in Dry Eye

    08 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240508055946/en

    BUSINESSWIRE
    08 May 2024
    Share Share
    Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
    Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

    29 Mar 2024

    // PRESS RELEASE

    https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-clinical-development-plan

    PRESS RELEASE
    29 Mar 2024
    Share Share